Seattle Genetics Presents New Data on Adcetris at European Symposium

At the 9th International Symposium on Hodgkin Lymphoma (ISHL), Seattle Genetics has highlighted a number of data presentations related it its antibody drug conjugate, Adcetris.

The symposium was held over the weekend of Oct. 12-15, 2013 in Cologne, Germany.

Adcetris is an antibody-drug conjugate that targets the CD30 protein, expressed on the cell surface in both Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. The European Commission granted conditional marketing authorization to Seattle Genetics for Adcetris in October of 2012 for the treatment of relapsed or refractory Hodgkin's and systemic anaplastic large cell lymphoma.

Establishing a 'foundation therapy'

Said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics:

We are evaluating Adcetris broadly in more than 20 ongoing clinical trials, including four global phase 3 trials in earlier lines of therapy for HL and mature T-cell lymphoma, as well as relapsed cutaneous T-cell lymphoma. Our goal is to establish Adcetris as the foundation of therapy for CD30-positive malignancies and improve the therapeutic outcome for patients.

In a step towards achieving those ends, the company presented three oral and nine poster presentations illustrating the broad clinical development program for Adcetris against Hodgkin's. These presentations included data from a phase 1 frontline advanced disease trial and a poster presentation describing the ongoing global phase III 'ECHELON-1' clinical trial in frontline Hodgkin's.

Adcetris remains a second-line therapy for Hodgkin's treatment, a status Seattle Genetics would like to see changed.

Source: ISHL